Japan-based pharmaceutical company Astellas Pharma Inc. agreed to settle an antitrust lawsuit ahead of trial, which was set to begin last Tuesday in Boston federal court. The Louisiana Wholesale Drug Co. and other plaintiffs had filed five lawsuits against Astellas in 2011 accusing it of illegally holding a monopoly on the market for Tacrolimus, sold under the brand name Prograf.
The allegations claimed Astellas made tactical efforts to keep the generic version of the anti-rejection, immune-suppressant drug off store shelves. Specifically, plaintiffs argued that Astellas filed a “sham” petition in 2007 seeking safety and efficacy test for the generic version of the drug in efforts to delay its entry onto the market. Details of the settlement were not disclosed.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Veteran Lawyers Launch Boutique Antitrust Firm in NY and DC
Oct 6, 2024 by
CPI
EU’s Top Court Upholds Antitrust Veto on Thyssenkrupp-Tata Steel Deal
Oct 6, 2024 by
CPI
Brazil’s Court Delays X’s Return Over Fine Payment Dispute
Oct 6, 2024 by
CPI
Tencent and Guillemot Family Consider Potential Buyout of Ubisoft
Oct 6, 2024 by
CPI
Second Price-Fixing Case Against Hotel-Casinos Dismissed by Federal Judge
Oct 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh